Researcher
Els Van Nieuwenhuysen
- Disciplines:Gynaecology and obstetrics, Nursing, Endocrinology and metabolic diseases
Affiliations
- Department of Oncology (Department)
Member
From1 Sep 2015 → 31 Oct 2017 - Gynaecological Oncology (Division)
Member
From1 Aug 2012 → Today
Projects
1 - 4 of 4
- ORDECA – ORganoid Drug screening for Endometrial CAncerIdentifying novel drugs and biomarkers for treating endometrial cancer using a high-throughput patient-derived organoid drug discovery and screening platformFrom1 Oct 2023 → TodayFunding: IOF - technology validation in lab
- Abemaciclib and letrozole in ER positive rare ovarian cancerFrom1 Mar 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Efficacy of abemaciclib and letrozole in estrogen receptor-positive rare ovarian cancer and unravelling mechanisms of response and resistanceFrom1 Jan 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Exploring the heterogeneity of rare ovarian cancerDefining (epi)genomic transition from precursor lesion to invasive rare ovarian cancerFrom1 Apr 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
71 - 80 of 100
- Imaging in gynecological disease: clinical and ultrasound features of immature teratomas of the ovary.(2016)
Authors: An Coosemans, Chiara Landolfo, Wouter Froyman, Ben Van Calster, Jan Verbakel, Els Van Nieuwenhuysen, Ignace Vergote, Dirk Timmerman
Pages: 1 - 50 - Assessing the genetic architecture of epithelial ovarian cancer histological subtypes(2016)
Authors: Diether Lambrechts, Els Van Nieuwenhuysen, Ignace Vergote, Adriaan Vanderstichele
Pages: 741 - 56 - Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer (vol 53, pg 51, 2016)(2016)
Authors: Sandrina Lambrechts, Dominiek Smeets, Matthieu Moisse, Elena Ioana Braicu, Adriaan Vanderstichele, Hui Zhao, Els Van Nieuwenhuysen, Els Berns, Jalid Sehouli, Robert Zeillinger, et al.
Pages: 226 - 226 - Ovarian cancer in children and adolescents: A rare disease that needs more attention(2016)
Authors: Thaïs Baert, Els Van Nieuwenhuysen, Anne Uyttebroeck, Ignace Vergote, An Coosemans
Pages: 3 - 8 - Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study(2016)
Authors: Diether Lambrechts, Ignace Vergote, Els Van Nieuwenhuysen
Pages: 884 - 95 - No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer(2016)
Authors: Diether Lambrechts, Sandrina Lambrechts, Patrick Neven, Benoit Beuselinck, Dominiek Smeets, Els Van Nieuwenhuysen, Ignace Vergote, Caroline Weltens
Pages: 386 - 401 - No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer(2016)
Authors: Breast Cancer Association Consortium, and Consortium of Modi Ovarian Cancer Association Consortium, Antoinette Hollestelle, Frederieke H van der Baan, Andrew Berchuck, Sharon E Johnatty, Katja K Aben, Bjarni A Agnarsson, Kristiina Aittomäki, Elisa Alducci, Irene L Andrulis, et al.
Pages: 386 - 401 - Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium(2016)
Authors: Ignace Vergote, Els Van Nieuwenhuysen
Pages: 1015 - 22 - The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study(2016)
Authors: Ignace Vergote, Els Van Nieuwenhuysen
Pages: 3009 - 3016 - Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer(2016)
Authors: Diether Lambrechts, Evelyn Despierre, Els Van Nieuwenhuysen, Sandrina Lambrechts, Ignace Vergote
Pages: 6353 - 68